MTOR and acute myeloid leukemia: However, once patients stopped taking rapamycin, their lung function began to deteriorate (McCormack et al., 2011), or the AML tumor recurred (Bissler et al., 2008, 2013) due to the transient binding/inhibitory effects of rapamycin towards mTOR complex.